by Pfizer, BioNTech | Dec 20, 2022 | C19 (COVID-19), VC19 (VACCINES COVID-19), VE (VACCINE EFFECTIVENESS), VS (VACCINE SAFETY)
Motivation PROTOCOL for Pfizer Phase 1/2 & 3 SARS-CoV-2 RNA Vaccine Trials. This specifies the trial design and rules. PF-07302048 (BNT162 RNA-Based COVID-19 Vaccines) Author Pfizer. BioNTech. Submitted By Dr Herman Edeling Supported By Dr Stephen Schmidt Type of...
by CCCA, Deanna McLeod | Dec 20, 2022 | VC19 (VACCINES COVID-19), VE (VACCINE EFFECTIVENESS), VS (VACCINE SAFETY)
Motivation Expert analysis of the Pfizer studies “Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine”, published in the NEJM. Serious flaws identified in trial design, conduct, data collection and reporting. Unblinding and crossover after 2 months....
by Jeyanthi Kunadhasan | Dec 20, 2022 | C19 (COVID-19), VC19 (VACCINES COVID-19), VE (VACCINE EFFECTIVENESS)
Motivation The Pfizer mRNA “vaccine” trial 2-month data report “Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine”, claimed 95% EFFICACY on the basis of RRR (relative risk reduction) in only 170 trial participants out of the total of...
by Baruch Fischhoff, Noel T. Brewer, Julie S. Downs | Dec 15, 2022 | VC19 (VACCINES COVID-19), VE (VACCINE EFFECTIVENESS), VT (VACCINES TRADITIONAL)
You need to be a SAVIMS Member to view this page. IF YOU ARE A SAVIMS MEMBER PLEASE LOGIN HERE ...
